Paolo Tombesi insider trades: Turning Point Therapeutics (TPTX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Paolo reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jul 27, 2022 | TPTX | ↓ Sell | 1,183 | $74.94 | $89K | Direct | Jul 29, 2022 (2d) |
| Feb 4, 2021 | EPZM | ↓ Sell10b5-1 | 1,021 | $11.21 | $11K | Direct | Feb 5, 2021 (1d) |
| Jun 26, 2020 | EPZM | ↓ Sell10b5-1 | 1,805 | $16.15 | $29K | Direct | Jun 30, 2020 (4d) |
| Mar 25, 2020 | EPZM | ↓ Sell10b5-1 | 1,243 | $15.28 | $19K | Direct | Mar 26, 2020 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Paolo Tombesi's insider trades
Paolo Tombesi is EVP & Chief Financial Officer at Turning Point Therapeutics (TPTX). Since Mar 25, 2020, Paolo has reported no open-market purchases and 4 sales worth $148K on SEC Form 4. There have been no open-market trades in the last 12 months.
3 sales (40% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (11 filings), shares withheld for taxes (2 filings), shares returned to the company (1 filing), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every TPTX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.